Compare Sezzle Inc (SEZL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Summit Therapeutics Inc — how do they compare? Sezzle Inc trades at $118.51 (market cap $3.99B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Summit Therapeutics Inc is far larger — about 3.5× Sezzle Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SEZL | SMMT | |
|---|---|---|
Market Cap | $3.99B | $13.79B |
Sector | Technology | Health |
52-Week High | $188.55 | $26.38 |
52-Week Low | $50.97 | $12.43 |
Enterprise Value | $4.03B | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL trades at $118.35, down 1.85% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 30.35% net income margin and consistent earnings beats in recent quarters. Recent business developments include merchant network expansion with Gymshark and Debenhams Group, while analyst consensus remains bullish with a $161.17 price target representing 36% upside potential.
SEZL presents a compelling growth story with robust profitability metrics and expanding market presence, though technical weakness and high valuation multiples warrant caution. The stock offers significant upside based on analyst targets but faces execution risks in competitive fintech landscape and potential market volatility.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
